CR-1301 is under clinical development by Conaris Research Institute and currently in Phase III for Intestinal Infection. According to GlobalData, Phase III drugs for Intestinal Infection does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CR-1301 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CR-1301 overview
CR-1301 is under development for the treatment of chronic intestinal infections. It is a intestinal microenvironment transfer or fecal microbiota filtrate transfer. The drug candidate is developed based on filtration technology.
Conaris Research Institute overview
Conaris Research Institute (Conaris) is a biotechnological company that offers preclinical and early clinical development services. The company provides drugs for various inflammatory indications. Its pipeline product candidates includ CR15/01, CR12/01, CR12/02, CR13/01, FE999301 and conaskin tinktur. Conaris offers services such as development of new drugs, physical and chemical characterization, lead optimization, lab scale production and GMP development. It also develops in-house technology platform and a network of associated partners for the requirements of drug development candidates. Conaris is headquartered in Kiel, Schleswig-Holstein, Germany.
For a complete picture of CR-1301’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
